We provided more than 129 million doses of VERMOX® (mebendazole), our treatment for intestinal worms, to infected children in 14 countries in 2015.
In more than 100 countries, our HIV medicines are made available either at special-effort or reduced pricing.
Since 2010, five formulations of our HIV antiretroviral medicines have achieved World Health Organization prequalification to address developing world diseases.
By 2020, 175 million individuals will have benefited from solutions that prevent, control and eliminate global diseases.
By 2020, we will produce and donate one billion doses of VERMOX® (mebendazole) to treat greater than 100 million children at risk for intestinal worms.
Advance Global Health
Access to HIV Medicines
Achieve WHO Status for Antiretrovirals
Eliminating Global Diseases
Reducing Intestinal Worm Infections
Training Skilled Birth Attendants